You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR AMBIEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ambien

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00042146 ↗ Behavioral and Pharmacological Treatment for Insomnia Completed National Institute of Mental Health (NIMH) Phase 4 2001-12-01 This study will evaluate the long- and short-term effects of cognitive-behavior therapy (CBT), alone and in combination with zolpidem (Ambien®), for chronic insomnia.
NCT00042146 ↗ Behavioral and Pharmacological Treatment for Insomnia Completed Laval University Phase 4 2001-12-01 This study will evaluate the long- and short-term effects of cognitive-behavior therapy (CBT), alone and in combination with zolpidem (Ambien®), for chronic insomnia.
NCT00044629 ↗ Combined Behavioral/Pharmacological Therapy for Insomnia Completed National Institute of Mental Health (NIMH) Phase 2 2001-09-01 This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00044629 ↗ Combined Behavioral/Pharmacological Therapy for Insomnia Completed Duke University Phase 2 2001-09-01 This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00086281 ↗ Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed Jazz Pharmaceuticals Phase 4 2003-11-01 To study the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in patients with obstructive sleep apnea syndrome (OSAS).
NCT00156533 ↗ Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing Completed Sanofi-Synthelabo Phase 4 2005-03-01 We want to assess whether "how and when" one takes sleep medication results in similar or different outcomes with respect to symptom relief. We also want to know whether taking medication for a period of time provides continued benefit once the medication is stopped.
NCT00156533 ↗ Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing Completed University of Rochester Phase 4 2005-03-01 We want to assess whether "how and when" one takes sleep medication results in similar or different outcomes with respect to symptom relief. We also want to know whether taking medication for a period of time provides continued benefit once the medication is stopped.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ambien

Condition Name

Condition Name for Ambien
Intervention Trials
Healthy 9
Insomnia 8
Sleep 4
Sleep Initiation and Maintenance Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ambien
Intervention Trials
Sleep Initiation and Maintenance Disorders 20
Depression 5
Parasomnias 3
Depressive Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ambien

Trials by Country

Trials by Country for Ambien
Location Trials
United States 73
Canada 4
India 2
Germany 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ambien
Location Trials
California 8
Pennsylvania 8
New York 6
Massachusetts 5
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ambien

Clinical Trial Phase

Clinical Trial Phase for Ambien
Clinical Trial Phase Trials
Phase 4 18
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ambien
Clinical Trial Phase Trials
Completed 40
Unknown status 2
Not yet recruiting 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ambien

Sponsor Name

Sponsor Name for Ambien
Sponsor Trials
Sanofi 6
National Institute of Mental Health (NIMH) 6
National Institutes of Health (NIH) 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ambien
Sponsor Trials
Other 37
Industry 25
U.S. Fed 14
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ambien (Zolpidem Tartrate): Clinical Trials, Market Analysis, and Projections

Overview of Ambien

Ambien, known generically as zolpidem tartrate, is a widely used sleep medication designed to help patients with difficulties initiating sleep. It is a gamma-aminobutyric acid (GABA) receptor agonist, which means it enhances the activity of GABA, a neurotransmitter that helps to calm the brain[4].

Clinical Trials and Efficacy

Historical Context and Trials

Ambien has been extensively studied in various clinical trials to assess its efficacy and safety. One notable comparison involves the SUNRISE 1 clinical trial, which evaluated the efficacy of another sleep aid, lemborexant, against zolpidem tartrate. In this trial, participants received either placebo, zolpidem tartrate extended release (6.25 mg), or lemborexant (5 mg or 10 mg) for one month. The study found that while zolpidem tartrate improved sleep onset, lemborexant showed superior results in both sleep onset and maintenance[1].

Mechanism of Action

Zolpidem tartrate works by modulating the GABA receptors, specifically the alpha-1 and gamma-3 subunits. This action helps in reducing the time to fall asleep, making it effective for patients with insomnia characterized by difficulties in initiating sleep[4].

Market Analysis

Current Market Size and Sales

As of the latest data, the U.S. annual sales for Ambien and Ambien CR (the controlled-release version) were $39 million for the 12 months ended April 2024. This figure indicates a stable demand for the medication in the U.S. market[5].

Market Trends and Growth

The sleep aids market, which includes medications like Ambien, is projected to grow significantly. A report by Infinium Global Research estimated that the global sleep aids market will reach $114.15 billion by 2025, growing at a compound annual growth rate (CAGR) of 7.0% from 2019 to 2025. This growth is driven by increasing consumer awareness, changing lifestyles, and the rising prevalence of sleep disorders[2].

Competitive Landscape

The insomnia market is dominated by dual orexin receptor antagonists (DORAs), which include medications like Belsomra (suvorexant) and Dayvigo (lemborexant). These newer medications have been gaining market share from traditional hypnotics, including zolpidem tartrate. However, zolpidem tartrate remains a popular choice due to its established presence and efficacy in treating insomnia[3].

Market Projections

Future Growth and Challenges

The insomnia market across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) is expected to grow at a CAGR of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032. This growth will be driven by the increasing use of DORAs and the introduction of new pipeline products. However, the market may face challenges such as the loss of market exclusivity for key DORAs, which could lead to the entry of generic versions and subsequent sales erosion[3].

Impact of Generic Versions

Belsomra is set to lose market exclusivity in the US in 2029 and Japan in 2031, while Dayvigo will lose its exclusivity in the US in 2031. This will allow cheaper generic versions to enter the market, potentially affecting the sales of branded medications like Ambien. However, the established brand loyalty and the continued need for effective sleep aids are expected to maintain a significant market presence for Ambien[3].

Recent Developments

Acquisition by Cosette Pharmaceuticals

In a recent development, Cosette Pharmaceuticals acquired Ambien and Ambien CR from Sanofi US, ensuring a seamless transition and continued supply of these medications to patients. This acquisition strengthens Cosette’s portfolio and reaffirms its commitment to providing high-quality products to patients worldwide[5].

Key Takeaways

  • Efficacy and Mechanism: Ambien (zolpidem tartrate) is effective in reducing sleep onset time by modulating GABA receptors.
  • Market Size and Sales: The U.S. annual sales for Ambien and Ambien CR were $39 million as of April 2024.
  • Market Growth: The global sleep aids market is projected to reach $114.15 billion by 2025, with a CAGR of 7.0%.
  • Competitive Landscape: The insomnia market is shifting towards DORAs, but traditional hypnotics like zolpidem tartrate remain relevant.
  • Future Projections: The insomnia market is expected to grow at a CAGR of 2.6% from 2022 to 2032, despite challenges from generic versions.
  • Recent Developments: Cosette Pharmaceuticals has acquired Ambien and Ambien CR, ensuring continued supply and strengthening their product portfolio.

FAQs

What is the primary mechanism of action of Ambien?

Ambien works by modulating the gamma-aminobutyric acid (GABA) receptors, specifically the alpha-1 and gamma-3 subunits, to enhance the activity of GABA and help patients fall asleep[4].

How does Ambien compare to newer sleep aids like lemborexant?

In clinical trials, lemborexant has shown superior results in both sleep onset and maintenance compared to zolpidem tartrate. However, zolpidem tartrate remains effective for patients with difficulties initiating sleep[1].

What is the projected growth of the sleep aids market?

The global sleep aids market is estimated to reach $114.15 billion by 2025, growing at a CAGR of 7.0% from 2019 to 2025[2].

What are the challenges facing the insomnia market in the future?

The market may face challenges such as the loss of market exclusivity for key DORAs, leading to the entry of generic versions and potential sales erosion[3].

Who acquired Ambien and Ambien CR from Sanofi US?

Cosette Pharmaceuticals acquired Ambien and Ambien CR from Sanofi US, ensuring a seamless transition and continued supply of these medications to patients[5].

Sources

  1. Comparison of Lemborexant With Placebo and Zolpidem Tartrate... - JAMA Network Open
  2. Sleep Aids Market Worth $114.15 Billion by 2025 - PR Newswire
  3. Dual orexin receptor antagonists to drive insomnia market across... - Clinical Trials Arena
  4. Zolpidem: Uses, Interactions, Mechanism of Action - DrugBank Online
  5. Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market - BioSpace
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.